The biotech companies Shire and NanoMedSyn have launched a new research partnership to evaluate a potential treatment for lysosomal storage disorders including Pompe disease. NanoMedSyn has developed an enzyme replacement therapy using proprietary technology called AMFA that was shown in preclinical models to have promising biological activity.
treatment
Recent Posts
- Part of our journey was learning how to talk to our children about Pompe
- Early Pompe disease treatment means better heart health: Study
- MDA 2026: Keynote speaker to MDA community: ‘Your voice is powerful’
- I enforce lifesaving care to protect my child now and prepare her for the future
- Sugar marker found in urine could help track progression in LOPD: Study